Friday, November 22nd, 2024

Parkway Life REIT: Steady Growth Amid Strategic Expansion and Robust Capital Management

Broker Name: OCBC Investment Research
Date: 21 October 2024


Investment Rating

  • Rating: BUY (as of 21 October 2024)
  • Last Close: SGD 3.99
  • Fair Value Estimate: SGD 4.48
  • Parkway Life REIT (PLIFE) maintains a stable outlook amidst challenging market conditions. The REIT’s strong fundamentals and strategic capital management make it a favorable option for long-term investors.

Recent Financial Performance

  • 9M24 Distribution per Unit (DPU): Grew by 2.8% year-on-year (YoY) to 11.3 Singapore cents. Despite the depreciation of the Japanese yen (JPY), distributable income was safeguarded through JPY net income hedges.
  • Gearing: Increased to 37.5% as of 30 September 2024, following the acquisition of a nursing home in Osaka, Japan. However, the all-in cost of debt remains low at 1.36%.
  • Gross Revenue and Net Property Income (NPI): For 9M24, gross revenue and NPI declined by 2.2% and 2.1% YoY, respectively. The JPY depreciation was partially offset by new contributions from acquired nursing homes in Japan and rental step-ups.
  • Distributable Income: Amounted to SGD 68.3 million for 9M24, translating to a DPU of 11.3 Singapore cents (or 3.76 Singapore cents for 3Q24). This meets 73.7% of the full-year DPU forecast.

Investment Thesis

PLIFE is one of Asia’s largest listed healthcare REITs, with a robust portfolio of 64 healthcare assets across Singapore, Malaysia, and Japan. The REIT is known for its long-term lease structures, offering stability and growth potential through rental escalations and acquisitions.

  • Defensive Sector: Healthcare REITs are typically defensive, with PLIFE benefitting further from its diversified healthcare assets.
  • Portfolio: Comprises private hospitals and medical centers in Singapore and Malaysia, and nursing homes in Japan, totaling a portfolio valuation of SGD 2.25 billion as of 30 September 2024.
  • Growth Potential: Continued potential for growth supported by trends such as increasing foreign medical tourism in Singapore and an aging population in Japan.

Capital Management

  • Gearing and Debt Management: Gearing rose slightly due to recent acquisitions but remains manageable at 37.5%. About 87% of interest rate exposure is hedged, and the all-in cost of debt is stable at 1.36%.
  • Loan Refinancing: The REIT has refinanced maturing loans due in 2025, including a short-term loan linked to recent acquisitions. This extends the weighted average debt term to 3.8 years, with no significant refinancing needed until September 2026.

Valuation and Performance

  • Current Valuation: Trading at a forward 12-month price-to-book (P/B) ratio of 1.6x and a forward dividend yield of 3.7%, which are below and above the five-year historical averages, respectively.
  • Investment Outlook: Long-term investors can consider buying on price pullbacks ahead of anticipated significant DPU growth, particularly after 2026, when renovation works at Mount Elizabeth Hospital are completed.

ESG Overview

  • ESG Rating: Maintained as of December 2023. Although PLIFE actively promotes energy conservation, the proportion of green-certified buildings remains limited. Corporate governance could be improved with more independent board members.
  • Business Ethics: A robust framework, including whistleblower protection, positions PLIFE ahead of many global peers.

Key Risks

  • Interest Rates and Funding Costs: High interest rates could affect distributable income, impacting growth prospects.
  • Tenant Issues: Risks include tenant defaults or refusal to renew leases, particularly in Japan.
  • Cost Overruns: Potential overruns from capital expenditure programs or asset enhancement initiatives.

Future Catalysts

  • Accretive Acquisitions: Further growth through acquisitions that enhance the DPU.
  • Japanese Yen (JPY) Dynamics: A hawkish Bank of Japan (BoJ) could strengthen the JPY, which would positively impact PLIFE’s income.
  • Rental Upside: Higher-than-expected performance of Singapore assets or successful renegotiation of Japan leases could drive additional revenue.

Conclusion

Parkway Life REIT continues to exhibit robust growth and stability. With a strategic approach to acquisitions, prudent debt management, and resilience in a defensive sector, it remains a solid investment for those seeking long-term income stability.

Malakoff Corporation: A Strategic Player in Malaysia’s Rising Power Demand and Renewable Energy Expansion

Date: September 23, 2024Broker Name: CGS International Securities Malakoff Corporation’s Role in Meeting Malaysia’s Power Demand Malakoff Corporation is positioned as a significant player in addressing Malaysia’s growing power demand, particularly driven by the...

Banpu’s Coal Stabilizes, Gas Challenges Persist: Analyst Insights and 2025 Outlook

Banpu Public Co Ltd: A Strategic Analysis Banpu Public Co Ltd: A Strategic Analysis Date: November 18, 2024 Broker: UOB Kay Hian Overview of Banpu Public Co Ltd Banpu Public Co Ltd is a...

Gamuda: A Strategic Buy as Hydro Project Wins Propel Margin Recovery

Date of Report October 28, 2024 Broker Name CGS International Company Overview Gamuda is a prominent Malaysian infrastructure and property development company known for its involvement in various construction projects, including highways, railways, and...